Stability Indicating Rp-Hplc for Method Development and Validation for Simultaneous Estimation of Empagliflozin and Nateglinide in Bulk Drug

. Kajol; Aditi Kaushik; Nikhil Sharma

doi:10.35516/jjps.v18i2.2648

Authors

. Kajol Department of Pharmaceutical Analysis & Quality Assurance, Laureate Institute of Pharmacy, Kathog, Kangra, India
Aditi Kaushik Department of Pharmaceutical Analysis & Quality Assurance, Laureate Institute of Pharmacy, Kathog, Kangra, India
Nikhil Sharma Department of Pharmaceutical Analysis & Quality Assurance, Laureate Institute of Pharmacy, Kathog, Kangra, India

DOI:

https://doi.org/10.35516/jjps.v18i2.2648

Keywords:

Empagliflozin, RP-HPLC, Method validation, Stability indicating method, Nateglinide

Abstract

A simple, accurate, and precise stability-indicating RP-HPLC method was developed and validated for the simultaneous estimation of Empagliflozin and Nateglinide in bulk drug form. Chromatographic separation was performed on a Shim-pack C-18 column (250 × 4.6 mm, 5 µm) using a mobile phase of Acetonitrile: Water (90:10, v/v) adjusted to pH 3. The UV detection wavelength was set at 216 nm, the flow rate was maintained at 1 mL/min, and the injection volume was 20 µL. The retention times for Empagliflozin and Nateglinide were found to be 2.770 and 3.682 minutes, respectively. This method was validated according to ICH Q2(R1) guidelines for linearity, accuracy, precision, limit of detection (LOD), limit of quantification (LOQ), and robustness. A linear response was observed in the concentration range of 5–25 µg/mL for Empagliflozin and 10–50 µg/mL for Nateglinide. The LOD and LOQ for Empagliflozin were found to be 14.0502 µg/mL and 42.576 µg/mL, respectively, while for Nateglinide, they were 6.5398 µg/mL and 19.8178 µg/mL. Stress studies were performed in accordance with ICH Q1A(R2) guidelines. The drugs were subjected to stress conditions including photolytic, oxidative, thermal degradation, and acid/base hydrolysis to develop a stability-indicating method. The degraded products were effectively extracted and analyzed from the sample.

References

Athyros V.G., Doumas M., Imprialos K.P., Stavropoulos K., Georgianou E., Katsimardou A., and Karagiannis A. Diabetes and lipid metabolism. Hormones. 2018; 17:61–67. DOI: https://doi.org/10.1007/s42000-018-0014-8

Sarkar B.K., Akter R., Das J., Das A., Modak P., Halder S., Sarkar A.P., and Kundu S.K. Diabetes mellitus: A comprehensive review. Journal of Pharmacognosy and Phytochemistry. 2019; 8(6):2362–2371.

Kahn B.B. Type 2 diabetes: when insulin secretion fails to compensate for insulin resistance. Cell. 1998; 92(5):593–596. DOI: https://doi.org/10.1016/S0092-8674(00)81125-3

Mukhtar Y., Galalain A., and Yunusa U. A modern overview on diabetes mellitus: a chronic endocrine disorder. European Journal of Biology. 2020; 5(2):1–14. DOI: https://doi.org/10.47672/ejb.409

Soumya D., and Srilatha B. Late stage complications of diabetes and insulin resistance. J Diabetes Metab. 2011; 2(9):1000167. DOI: https://doi.org/10.4172/2155-6156.1000167

Cusi K. The epidemic of type 2 diabetes mellitus: its links to obesity, insulin resistance, and lipotoxicity. Diabetes and Exercise. 2009; pp.3–54. DOI: https://doi.org/10.1007/978-1-59745-260-1_1

Soares E., Nunes S., Reis F., and Pereira F.C. Diabetic encephalopathy: the role of oxidative stress and inflammation in type 2 diabetes. International Journal of Interferon, Cytokine and Mediator Research. 2012; 75–85. DOI: https://doi.org/10.2147/IJICMR.S29322

Khursheed R., Singh S.K., Wadhwa S., Kapoor B., Gulati M., Kumar R., Ramanunny A.K., Awasthi A., and Dua K. Treatment strategies against diabetes: Success so far and challenges ahead. European Journal of Pharmacology. 2019; 862:172625. DOI: https://doi.org/10.1016/j.ejphar.2019.172625

Ahmed K.A.A., Muniandy S., and Ismail I.S. Type 2 diabetes and vascular complications: A pathophysiologic view. Biomedical Research-India. 2010; 21(2):147–155.

Wild S., Roglic G., Green A., Sicree R., and King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004; 27(5):1047–1053. DOI: https://doi.org/10.2337/diacare.27.5.1047

Shahi A., Prasad V.S., Imam S.S., Muheem A., and Jahangir M.A. Pathophysiological ramifications of diabetic condition: a review. Asian Journal of Biomedical and Pharmaceutical Sciences. 2018; 8:28–38. DOI: https://doi.org/10.4066/2249-622X.65.18-845

Ozougwu J.C., Obimba K.C., Belonwu C.D., and Unakalamba C.B. The pathogenesis and pathophysiology of type 1 and type 2 diabetes mellitus. J Physiol Pathophysiol. 2013; 4(4):46–57. DOI: https://doi.org/10.5897/JPAP2013.0001

Quesada I., Tudurí E., Ripoll C., and Nadal A. Physiology of the pancreatic α-cell and glucagon secretion: role in glucose homeostasis and diabetes. Journal of Endocrinology. 2008; 199(1):5–19. DOI: https://doi.org/10.1677/JOE-08-0290

Sharabi K., Tavares C.D., Rines A.K., and Puigserver P. Molecular pathophysiology of hepatic glucose production. Molecular Aspects of Medicine. 2015; 46:21–33. DOI: https://doi.org/10.1016/j.mam.2015.09.003

Larsson K., Elding‐Larsson H., Cederwall E., Kockum K., Neiderud J., Sjöblad S., Lindberg B., Lernmark B., Cilio C., Ivarsson S.A., and Lernmark Å. Genetic and perinatal factors as risk for childhood type 1 diabetes. Diabetes/Metabolism Research and Reviews. 2004; 20(6):429–437. DOI: https://doi.org/10.1002/dmrr.506

Yong H.Y., Mohd Shariff Z., Mohd Yusof B.N., Rejali Z., Tee Y.Y.S., Bindels J., and van Der Beek E.M. Independent and combined effects of age, body mass index and gestational weight gain on the risk of gestational diabetes mellitus. Scientific Reports. 2020; 10(1):8486. DOI: https://doi.org/10.1038/s41598-020-65251-2

World Health Organization. WHO Global report on diabetes. World Health Organization. 2016.

Shukla M., Khanna R.S., Shukla M., Mishra A., Singh A., Gupta B., Shukla M., Shukla S.M., Singh N.P., Chaterjee R., and Srivastava P. The Indian Journal of Research.

Gromada J., Franklin I., and Wollheim C.B. α-Cells of the endocrine pancreas: 35 years of research but the enigma remains. Endocrine Reviews. 2007; 28(1):84–116. DOI: https://doi.org/10.1210/er.2006-0007

Norton L., Shannon C., Gastaldelli A., and DeFronzo R.A. Insulin: The master regulator of glucose metabolism. Metabolism. 2022; 129:155142. DOI: https://doi.org/10.1016/j.metabol.2022.155142

Neumiller J.J. Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. Drugs in Context. 2014; 3.

Ndefo U.A., Anidiobi N.O., Basheer E., and Eaton A.T. Empagliflozin (Jardiance): a novel SGLT2 inhibitor for the treatment of type-2 diabetes. Pharmacy and Therapeutics. 2015; 40(6):364.

Kowalska K., Walczak J., Femlak J., Młynarska E., Franczyk B., and Rysz J. Empagliflozin—A new chance for patients with chronic heart failure. Pharmaceuticals. 2021; 15(1):47. DOI: https://doi.org/10.3390/ph15010047

Tentolouris N., Voulgari C., and Katsilambros N. A review of nateglinide in the management of patients with type 2 diabetes. Vascular Health and Risk Management. 2007; 3(6):797–807.

Ashcroft F.M., and Gribble F.M. ATP-sensitive K⁺ channels and insulin secretion: their role in health and disease. Diabetologia. 1999; 42(8):903. DOI: https://doi.org/10.1007/s001250051247

Weaver M.L., Orwig B.A., Rodriguez L.C., Graham E.D., Chin J.A., Shapiro M.J., McLeod J.F., and Mangold J.B. Pharmacokinetics and metabolism of nateglinide in humans. Drug Metabolism and Disposition. 2001; 29(4):415–421.

ICH Guideline. Validation of analytical procedures: text and methodology. Q2 (R1). 2005; 1(20):05.

Rignall A. ICHQ1A (R2) stability testing of new drug substance and product and ICHQ1C stability testing of new dosage forms. ICH Quality Guidelines: An Implementation Guide. 2017; 3–44. DOI: https://doi.org/10.1002/9781118971147.ch1

Alzweiri M., Sweidan K., and Aqel Q. Investigation of the chemical stability of lenalidomide in methanol/ethanol solvents using RP-HPLC-UV and LC-MS. Jordan Journal of Pharmaceutical Sciences. 2022; 15(3):305–314. DOI: https://doi.org/10.35516/jjps.v15i3.406

Bharti A.A., and Jeyaseelan C. Quantification of potential impurities present in testosterone undecanoate active pharmaceutical ingredient by stability indicating HPLC method using UV detector. Jordan Journal of Pharmaceutical Sciences. 2019; 12(1):1–15.

Sonawane S.S., Joshi G.J., and Kshirsagar S.J. Development and validation of HPLC method for quantification of zonisamide in spiked human plasma. Jordan Journal of Pharmaceutical Sciences. 2022; 15(1):40–50. DOI: https://doi.org/10.35516/jjps.v15i1.288